Importantly, PIKfyve inhibition by apilimod or ESK981 also led to upregulation of tumor-specific MHC-I surface expression (Fig. 4C) and an increase in intratumoral activated CD8+ T cells (Fig. 4D). Here, PIKFYVE is linked to neoplasm.